ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has launched www.MuGard.com. The patient- and healthcare professional- focused site is a comprehensive resource offering educational material on oral mucositis, patient analysis, MuGard product and how-to-order information.
"We are proud to have launched our product website as it resource for patients and healthcare professionals," said Frank Jacobucci, VP of Sales and Marketing for Access Pharmaceuticals, Inc. He continued, "Keeping the patient in mind, we constructed an easy-to-navigate MuGard destination where both patients and doctors can go to learn about oral mucositis, symptoms and the benefit that MuGard provides someone undergoing radiation and chemotherapy for various types of cancers, including head and neck cancers, such as throat cancer. By starting MuGard on the first day of anticancer regimens, as shown in the clinical data, a significant number of patients can significantly reduce the occurrence, duration and severity of oral mucositis. MuGard – first day, every day."
Oral mucositis is a debilitating side effect of radiotherapy and/or chemotherapy. Characterized by painful inflammation, mouth sores and ulceration of the mucous membranes lining the digestive tract, oral mucositis often times interferes with continued cancer therapy. MuGard is an FDA-approved, ready-to-use mucoadhesive oral rinse for the management of oral mucositis.
Breakthrough imaging method enhances precision in prostate cancer treatment